Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Management expects growth acceleration to double digits starting Q4 FY‘26. The company aims for double-digit growth starting Q4 FY '26, targeting over 10% growth, above the industry's 7.5%-8.5% expected growth.
From Jagsonpal Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Management expects growth acceleration to double digits starting Q4 FY‘26.
- Industry growth rate assumed around 7.5%-8.5%, with company targeting 50% higher growth than the industry, i.e., above 10%.
- Long-term outlook remains steady organic growth of 12%-14% over 3-4 years, barring macro/external changes.
- Growth to be driven by both volume expansion and price increases, with new product launches contributing significantly.
- Volume growth is expected to improve, supported by increased prescriber base and prescriptions per doctor.
- Strategic resource reallocation and brand rationalization aims to focus on larger, high-growth brands.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Jagsonpal Pharmaceuticals follows an asset-light model with most manufacturing outsourced, implying limited need for large capex.
- The company is focused on strategic capital deployment, primarily through acquisitions that are EBITDA accretive and value-adding.
- Currently, the management is seriously looking at acquisition candidates but notes that assets are highly priced, so disciplined M&A is key.
- Apart from acquisitions, some capital may be deployed towards organic growth in the form of product launches in high growth areas expected by end of H1 FY 2027.
- If suitable acquisitions are not found, the company may consider returning cash to shareholders.
2 more points from Jagsonpal Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹64 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jagsonpal Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Jagsonpal Pharmaceuticals Ltd Q3 FY26 results?
Management expects growth acceleration to double digits starting Q4 FY‘26. The company aims for double-digit growth starting Q4 FY '26, targeting over 10% growth, above the industry's 7.5%-8.5% expected growth.
What is Jagsonpal Pharmaceuticals Ltd share price analysis?
Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?
Jagsonpal Pharmaceuticals follows an asset-light model with most manufacturing outsourced, implying limited need for large capex.
Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.